EichorEICHOR
Location: Mainz Synced from ClinicalTrials.gov · August 08, 2026

Clinical studies recruiting near Mainz

Studies with at least one listed site matching this location on the public registry. Each page explains the study in plain language, with locations and study-team contacts. Clinicians: generate a printable list for your patient →

Futibatinib in Combination With (Chemo)Immunotherapy in Colorectal Cancer and Other Solid Tumor Entities
Phase 2 · Universitätsmedizin Mainz · Institut für Klinische Krebsforschung IKF GmbH at Krankenhau · NCT06722183
Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN
Phase 3 · Novartis Investigative Site · Novartis Pharmaceuticals · NCT05755386
Total Neoadjuvant Treatment With or Without Tislelizumab for Locally Advanced Rectal Cancer.
Phase 2 · Johannes Gutenberg-University Clinic, Mainz, Germany 1.Dept. · brenner baruch · NCT06940388
Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia
Phase 3 · Johannes Gutenberg University Mainz · Princess Maxima Center for Pediatric Oncology · NCT05327894
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Phase 3 · Universitätsmedizin Johannes Gutenberg Universität Mainz-Kli · Merck Sharp & Dohme LLC · NCT06393374
Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults
Phase N/A · Galderma Investigational Site 6373 · Galderma R&D · NCT06988605
A Study Evaluating the Effects of Filgotinib in Children and Teenagers With Ulcerative Colitis
Phase 3 · Universitaetsmedizin der Johannes Gutenberg-Universitaet Mai · Alfasigma S.p.A. · NCT06865417
Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer
Phase 3 · Universitätsmedizin Mainz · AGO Study Group · NCT05009082
PODOMOUNT-Basket, a Study to Test Whether BI 764198 Helps Adults and Adolescents With Different Types of Kidney Disease
Phase 2 · Universitätsmedizin der Johannes Gutenberg-Universität Mainz · Boehringer Ingelheim · NCT07355296
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants Wit
Phase 1/Phase 2 · Local Institution - 0026 · Bristol-Myers Squibb · NCT07291076
Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease
Phase 1/Phase 2 · UCT University Medical Center Mainz · CRISPR Therapeutics AG · NCT07549698
RAMIE Versus MIE for Resectable Esophageal Cancer, a Randomized Controlled Trial (ROBOT-2 Trial).
NA · University Medical Center Mainz · University Medical Center Mainz · NCT04306458
A Study of Bempedoic Acid in Combination With Ezetimibe and Either Rosuvastatin or Atorvastatin in Patients With Primary
Phase N/A · Kardiopraxis · Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company · NCT06686615
A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Pati
Phase 2 · Novartis Investigative Site · Novartis Pharmaceuticals · NCT06581198
A Study of Zasocitinib in Adults With Hidradenitis Suppurativa
Phase 2 · Universitaetsmedizin der Johannes Gutenberg-Universitaet Mai · Takeda · NCT07244263
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined
Phase 3 · Universitaetsmedizin der Johannes Gutenberg Universitaet Mai · Regeneron Pharmaceuticals · NCT06091865
DEfeating PEnile CAncer-2
NA · University Medical Center of Johannes Gutenberg-University · University Hospital Tuebingen · NCT07378670
International HIT-MED Registry (I-HIT-MED)
Phase N/A · University Hospital Mainz · Universitätsklinikum Hamburg-Eppendorf · NCT02417324
Prediction of Blood Pressure Outcomes Following Renal Denervation (PREDICT-RDN)
NA · Universitätsmedizin Mainz Kardiologie I · Heart Center Leipzig - University Hospital · NCT06845579
Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
Phase 1/Phase 2 · Universitätsklinikum Mainz · Heidelberg Pharma AG · NCT04879043
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
Phase 3 · Universitätsmedizin Johannes Gutenberg Universität Mainz · Bristol-Myers Squibb · NCT06976216
GMALL Registry and Collection of Biomaterial: Prospective Data Collection Regarding Diagnosis, Treatment and Outcome of
Phase N/A · Universitätsklinikum Mainz · Goethe University · NCT02872987
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
Phase N/A · Research Site · AstraZeneca · NCT06465810
EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin)
Phase 3 · Universitätsmedizin der Johannes Gutenberg-Universität Mainz · Boehringer Ingelheim · NCT06531824
Mucous Fistula Refeeding Reduces the Time From Enterostomy Closure to Full Enteral Feeds ("MUC-FIRE" Trial)
NA · Universitätsmedizin Mainz, Klinik und Poliklinik für Kinderc · University of Leipzig · NCT03469609
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic So
Phase 1/Phase 2 · Univ der Johannes GutenbergU · Daiichi Sankyo · NCT06330064
Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis
Phase 1 · University Medical Center of the Johannes Gutenberg-Universi · Regeneron Pharmaceuticals · NCT06975787
A Study to Find Out if BI 764198 Helps Adults and Adolescents With a Kidney Condition Called Focal Segmental Glomerulosc
Phase 3 · Universitätsmedizin der Johannes Gutenberg-Universität Mainz · Boehringer Ingelheim · NCT07220083
Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chron
Phase 2 · Novartis Investigative Site · Novartis Pharmaceuticals · NCT06865651
A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate
Phase 3 · Teva Investigational Site 32878 · Teva Branded Pharmaceutical Products R&D LLC · NCT06664619
Look up another city
Look up another condition